News & Updates

Vaccination protects the young against COVID-19

31 May 2023 by

COVID-19 remains a global health concern, and children and adolescents are equally affected. In fact, COVID-19 hospitalization rates in children increased during the Omicron era. [MMWR 2022;71:271-278] In children aged 5–11 years who were hospitalized during the predominance of Omicron, nearly 90 percent were unvaccinated. [MMWR 2022;71:574-581]

Vaccination protects the young against COVID-19

31 May 2023

Cidofovir tied to quicker lesion clearance in patients with monkeypox

30 May 2023

Treatment with topical cidofovir leads to faster clearance of skin lesions in patients with monkeypox but mild systemic involvement, according to a study. Time to resolution reduction can shorten isolation time and enhance the cosmetic impact in areas such as the face.

Cidofovir tied to quicker lesion clearance in patients with monkeypox

30 May 2023

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023 by

In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023

School-based program expands HPV vaccine uptake in SG

29 May 2023 by

A school-based immunization program in Singapore has resulted in high uptake and coverage of the human papillomavirus (HPV) vaccine, reports a study.

School-based program expands HPV vaccine uptake in SG

29 May 2023

Can azithromycin shorten shock resolution in ICU patients?

29 May 2023

Empiric azithromycin appears to have no substantial impact on shock duration, mechanical ventilation duration, intensive care unit (ICU) length of stay (LOS), hospital LOS, or in-hospital mortality in septic shock patients admitted to the ICU, according to a study.

Can azithromycin shorten shock resolution in ICU patients?

29 May 2023

New data fortify obeticholic acid role in NASH treatment

29 May 2023 by

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

New data fortify obeticholic acid role in NASH treatment

29 May 2023

Cognitive protection greater with intensive vs standard SBP lowering for high-risk individuals

29 May 2023

For individuals with increased projected risk of probable dementia or amnestic mild cognitive impairment (MCI) who are prescribed antihypertensive treatment, intensive systolic blood pressure (SBP) lowering confers greater cognitive benefits than standard treatment, according to a secondary analysis of the SPRINT trial.

Cognitive protection greater with intensive vs standard SBP lowering for high-risk individuals

29 May 2023

Clevidipine trumps nicardipine for BP control in patients undergoing cardiac surgery

28 May 2023

Treatment with clevidipine in patients undergoing cardiac surgery leads to better perioperative blood pressure (BP) control relative to nicardipine, with a slight rise in cost and no significant difference in safety outcomes, a study has found.

Clevidipine trumps nicardipine for BP control in patients undergoing cardiac surgery

28 May 2023

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

28 May 2023

Adding glucagon-like peptide-1 receptor agonists (GLP1RA) onto metformin, sulfonylurea, or insulin treatment alone or in combination appears to reduce the incidence of major adverse cardiac events (MACE) and heart failure (HF) hospitalization relative to treatment with dipeptidyl peptidase-4 inhibitors (DPP4i), suggests a study.

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

28 May 2023

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients

27 May 2023

Use of amiodarone in older patients with atrial fibrillation (AF) who are being treated with apixaban or rivaroxaban results in a higher risk of bleeding-related hospitalizations compared with the use of flecainide or sotalol, reports a study.

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients

27 May 2023

News & Updates

Filter by Specialty:

Specialty:

Vaccination protects the young against COVID-19

Vaccination protects the young against COVID-19

Cidofovir tied to quicker lesion clearance in patients with monkeypox

Cidofovir tied to quicker lesion clearance in patients with monkeypox

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

School-based program expands HPV vaccine uptake in SG

School-based program expands HPV vaccine uptake in SG

Can azithromycin shorten shock resolution in ICU patients?

Can azithromycin shorten shock resolution in ICU patients?

New data fortify obeticholic acid role in NASH treatment

New data fortify obeticholic acid role in NASH treatment

Cognitive protection greater with intensive vs standard SBP lowering for high-risk individuals

Cognitive protection greater with intensive vs standard SBP lowering for high-risk individuals

Clevidipine trumps nicardipine for BP control in patients undergoing cardiac surgery

Clevidipine trumps nicardipine for BP control in patients undergoing cardiac surgery

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients